TOKYO -- A pharmaceutical alliance between Japan's Eisai and U.S.-based Biogen has succeeded in developing the world's first therapeutic drug approved for slowing the onset of Alzheimer's disease.
On June 7, the U.S. Food and Drug Administration approved Aducanumab, a new drug developed by the two companies. Until now, there have been no drugs that can suppress the progression of dementia symptoms and this drug, the first new Alzheimer's treatment approved in the U.S. in 18 years, faced a bumpy road to get to this point.
